Edition:
United States

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

240.40CHF
11:29am EST
Change (% chg)

CHF-4.60 (-1.88%)
Prev Close
CHF245.00
Open
CHF244.50
Day's High
CHF244.60
Day's Low
CHF238.30
Volume
349,690
Avg. Vol
359,609
52-wk High
CHF278.40
52-wk Low
CHF164.23

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 1.11
Market Cap(Mil.): CHF18,244.84
Shares Outstanding(Mil.): 74.47
Dividend: 2.75
Yield (%): 1.12

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Lonza To Establish Cell- And Gene-Therapy Centers Of Excellence

* LONZA TO ESTABLISH CELL- AND GENE-THERAPY CENTERS OF EXCELLENCE TO ACCELERATE GROWTH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 14 2018

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Nov 02 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

Oct 03 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

Oct 03 2017

Earnings vs. Estimates